Betta Pharmaceuticals Co (SZSE:300558) 3-Year Book Growth Rate : 7.80% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co 3-Year Book Growth Rate?

Betta Pharmaceuticals Co's Book Value per Share for the quarter that ended in Mar. 2024 was ¥13.20.

During the past 12 months, Betta Pharmaceuticals Co's average Book Value per Share Growth Rate was 12.60% per year. During the past 3 years, the average Book Value per Share Growth Rate was 7.80% per year. During the past 5 years, the average Book Value per Share Growth Rate was 19.00% per year. During the past 10 years, the average Book Value per Share Growth Rate was 23.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Betta Pharmaceuticals Co was 51.00% per year. The lowest was -6.60% per year. And the median was 25.10% per year.

Competitive Comparison of Betta Pharmaceuticals Co's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Betta Pharmaceuticals Co's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's 3-Year Book Growth Rate falls into.

Betta Pharmaceuticals Co 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Betta Pharmaceuticals Co (SZSE:300558) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Betta Pharmaceuticals Co 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Betta Pharmaceuticals Co (SZSE:300558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » 3-Year Book Growth Rate

Traded in Other Exchanges

N/A

Address

No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN

Website

http://www.bettapharma.com

Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.

Executives

Wang Jia Bing	Directors, executives
Ding Lie Ming	Directors, executives
Cai Wan Yu	Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines